ESPERION
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.
ESPERION
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
1998-01-01
Address:
Ann Arbor, Michigan, United States
Country:
United States
Website Url:
http://www.esperion.com
Total Employee:
101+
Status:
Active
Contact:
734-332-0506
Total Funding:
764.15 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail IPv6 Microsoft Azure DNS GoDaddy DNS ReCAPTCHA V2 Microsoft
Similar Organizations
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Oberland Capital
Oberland Capital investment in Post-IPO Equity - Esperion
Longitude Capital
Longitude Capital investment in Venture Round - Esperion
Aisling Capital
Aisling Capital investment in Venture Round - Esperion
Domain Associates
Domain Associates investment in Venture Round - Esperion
Alta Partners
Alta Partners investment in Venture Round - Esperion
Asset Management Ventures (AMV)
Asset Management Ventures (AMV) investment in Venture Round - Esperion
Arboretum Ventures
Arboretum Ventures investment in Venture Round - Esperion
Arboretum Ventures
Arboretum Ventures investment in Series A - Esperion
Alta Partners
Alta Partners investment in Series A - Esperion
Domain Associates
Domain Associates investment in Series A - Esperion
Official Site Inspections
http://www.esperion.com Semrush global rank: 4.34 M Semrush visits lastest month: 2.63 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Esperion"
Esperion - Crunchbase Company Profile & Funding
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL …See details»
Esperion Corporate Presentation
Apr 1, 2020 profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes of legal …See details»
Esperion Therapeutics - Wikipedia
The first Esperion was founded in 1998 by Dr. Roger Newton to focus on the in-licensing and development of drugs to modulate HDL cholesterol (HDL-c). Pfizer acquired the original Esperion in February 2004 for US$1,300,000,000. It's believed this was a defensive move by Pfizer to prevent ETC-216 (apoA-1 Milano, Esperion's lead drug candidate) from falling into competitors' hands. ETC-216 increased the levels of ApoA-1, the major protein …See details»
Investors and Media | Esperion Therapeutics, Inc.
Dec 13, 2024 Esperion Contact Information: Investors: Alina Venezia [email protected] (734) 887-3903. Corporate Inquiries & Media: Tiffany Aldrich …See details»
Esperion Information - RocketReach
The NAICS codes for Esperion are [5417, 54, 54171, 541, 541714]. What is the SIC code for Esperion? The SIC codes for Esperion are [283, 28]. Top Esperion Employees Sheldon …See details»
ESPERION CORPORATE PRESENTATION - Seeking Alpha
And uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the impact of the ongoing COVID-19 pandemic on our …See details»
Esperion Therapeutics Company Description - Stock Analysis
2 days ago Company profile for Esperion Therapeutics, Inc. (LON: 0IIM) with a description, list of executives, contact details and other key facts.See details»
Esperion Therapeutics, Inc.
Explore Esperion Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 31 clinical trials, 69 news, and 86 literature, Disease Domain:Endocrinology and Metabolic …See details»
Esperion Therapeutics, Inc. (ESPR) - Yahoo Finance Canada
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its …See details»
Esperion - Funding, Financials, Valuation & Investors - Crunchbase
Esperion is registered under the ticker NASDAQ:ESPR . Their stock opened with $14.00 in its Jun 26, 2013 IPO. Stock Symbol NASDAQ:ESPR ; Valuation at IPO $196M; Money Raised at IPO …See details»
Esperion - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Esperion . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 6. ... Esperion has 8 board …See details»
Esperion - Overview, News & Similar companies | ZoomInfo.com
Esperion has recently released 2024 Q1 report with the following insight: Esperion is still in the early stages of leveraging its new labels and expanding patient access. It will take time for …See details»
Mission, Vision & Core Values of Esperion - CBM
Oct 2, 2024 Esperion is a forward-thinking pharmaceutical company dedicated to revolutionizing the field of lipid management and cardiovascular health. Our mission is to develop innovative …See details»
Esperion Employee Directory, Headcount & Staff | LeadIQ
Esperion Employee Directory . Pharmaceutical Manufacturing Michigan, United States 201-500 Employees. Official LinkedIn page for Esperion. At Esperion, we discover, develop, and …See details»
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan …
2 hours ago ANN ARBOR, Mich., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 43rd Annual …See details»
Esperion Partners with Neopharm to Commercialize NEXLETOL® …
Dec 12, 2024 – Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years – ... Esperion Contact …See details»
Working at Esperion - Great Place To Work®
79% of employees at Esperion say it is a great place to work . ... Today, our Trust Model™ offers an unmatched opportunity to identify what’s happening within your organization. Great Place …See details»
Esperion Therapeutics, Inc. (LON: 0IIM) - Stock Analysis
3 days ago Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein …See details»
Esperion Reports Third Quarter 2024 Financial Results and …
ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2024, and provided a …See details»
Working at Esperion Therapeutics: 19 Reviews - Indeed
Feb 6, 2024 Reviews from Esperion Therapeutics employees about Esperion Therapeutics culture, salaries, benefits, work-life balance, management, job security, and more. ... To say …See details»